MediciNova Completes Phase 2 Trial of Tipelukast for NAFLD and Hypertriglyceridemia in Type 2 Diabetes
核心洞察
MediciNova announced completion of last patient last visit in its Phase 2 MN-001-NATG-202 trial evaluating tipelukast for hypertriglyceridemia and NAFLD associated with type 2 diabetes.
The randomized, double-blind, placebo-controlled study enrolled patients to receive either 500 mg/day tipelukast or placebo for 24 weeks with co-primary endpoints measuring liver fat content and fasting triglycerides.
Tipelukast demonstrates multiple mechanisms of action including leukotriene receptor antagonism and phosphodiesterase inhibition, targeting both inflammatory and fibrotic pathways in liver disease.
MediciNova, Inc. has completed the last patient last visit (LPLV) in its Phase 2 clinical trial MN-001-NATG-202, evaluating the investigational drug MN-001 (tipelukast) for treating hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). The biopharmaceutical company announced the milestone on May 26, 2026, marking a significant step forward in developing treatments for metabolic complications associated with diabetes.
Trial Design and Endpoints
The MN-001-NATG-202 study represents a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate tipelukast's efficacy in addressing two interconnected metabolic conditions. Patients were randomized in a 1:1 ratio to receive either 500 mg/day of MN-001 (tipelukast) or placebo for 24 weeks.
The trial features two co-primary endpoints: change from baseline in liver fat content, measured by controlled attenuation parameter (CAP) score at Week 24, and change from baseline in fasting serum triglycerides at Week 24. Secondary endpoints encompass safety, tolerability, and changes in lipid profile parameters including HDL cholesterol, LDL cholesterol, and total cholesterol. Top-line data are expected in the third quarter of 2026.
Mechanism of Action and Therapeutic Rationale
MN-001 (tipelukast) is a novel, orally bioavailable, small-molecule compound that operates through multiple mechanisms to produce anti-inflammatory and antifibrotic activity in preclinical models. The drug's therapeutic effects are mediated through leukotriene receptor antagonism, inhibition of phosphodiesterase (primarily types 3 and 4), and inhibition of 5-lipoxygenase (5-LO).
The 5-LO/leukotriene pathway has been identified as a pathogenic factor in fibrosis development, making MN-001's inhibitory effect on this pathway a novel approach to treating fibrotic conditions. Preclinical studies have demonstrated that MN-001 down-regulates expression of genes that promote fibrosis, including LOXL2 (搜索), Collagen Type 1, and TIMP-1 (搜索). Additionally, the compound down-regulates expression of inflammatory genes, including CCR2 (搜索) and MCP-1 (搜索).
The drug also inhibits triglyceride synthesis in hepatocytes by blocking arachidonic acid uptake. Recent research has shown that MN-002, the major metabolite of MN-001, significantly enhanced cholesterol efflux in macrophages by upregulating key transport proteins ABCA1 (搜索) and ABCG1 (搜索).
Disease Context and Unmet Medical Need
Type 2 diabetes mellitus is a metabolic disorder characterized by insulin resistance, which plays a central role in developing dyslipidemia—abnormal levels of lipids in the blood. Hypertriglyceridemia (elevated triglycerides) is commonly observed in individuals with T2DM, resulting from increased hepatic lipid synthesis and impaired clearance of triglyceride-rich lipoproteins.
Hypercholesterolemia, particularly elevated LDL cholesterol and reduced HDL cholesterol, is also frequently seen in diabetic patients and contributes to higher atherosclerosis risk. Dyslipidemia not only worsens glycemic control but also increases the risk of cardiovascular complications and liver-related conditions such as NAFLD. NAFLD is considered a hepatic complication of insulin resistance and is frequently associated with T2DM and dyslipidemia.
Company Pipeline and Development Strategy
MediciNova is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small-molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), each with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development.
The company's lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 is also being evaluated in Phase 2 trials for Long COVID and substance dependence. MN-001 (tipelukast) was previously evaluated in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF), with the current NAFLD trial representing the second Phase 2 study for this compound.
MediciNova has established a strong track record of securing investigator-sponsored clinical trials funded through government grants, supporting its development programs across multiple therapeutic areas.